Related Experiment Video
Updated: Dec 22, 2025
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
A Kugler1, G Stuhler, P Walden
1Department of Urology, University of Göttingen, Germany. akugler@gwdg.de
Abstract:
Reports of spontaneous regressions of metastases and the demonstration of tumor-reactive cytotoxic T lymphocytes indicate the importance of the host's immune system in controlling the devastating course of metastatic renal cell carcinoma. Recent research indicates that immunization with hybrids of tumor and antigen presenting cells results in protective immunity and rejection of established tumors in various rodent models. Here, we present a hybrid cell vaccination study of 17 patients. Using electrofusion techniques, we generated hybrids of autologous tumor and allogeneic dendritic cells that presented antigens expressed by the tumor in concert with the co-stimulating capabilities of dendritic cells. After vaccination, and with a mean follow-up time of 13 months, four patients completely rejected all metastatic tumor lesions, one presented a 'mixed response', and two had a tumor mass reduction of greater 50%. We also demonstrate induction of HLA-A2-restricted cytotoxic T cells reactive with the Muc1 tumor-associated antigen and recruitment of CD8+ lymphocytes into tumor challenge sites. Our data indicate that hybrid cell vaccination is a safe and effective therapy for renal cell carcinoma and may provide a broadly applicable strategy for other malignancies with unknown antigens.
Insights
Hybrid cell vaccination shows promise for metastatic renal cell carcinoma. This therapy, using fused tumor and dendritic cells, led to complete tumor rejection or significant reduction in several patients, indicating a safe and effective treatment strategy.
Area of Science:
- Immunology
- Oncology
- Vaccine Development
Background:
- Metastatic renal cell carcinoma (RCC) course is influenced by the host immune system.
- Tumor-antigen presenting cell hybrids have shown efficacy in preclinical models.
- Spontaneous tumor regressions and tumor-reactive T cells highlight immune control potential.
Purpose of the Study:
- To evaluate the safety and efficacy of hybrid cell vaccination in patients with metastatic RCC.
- To assess the induction of anti-tumor immune responses following vaccination.
Main Methods:
- Generation of hybrid cells via electrofusion of autologous tumor cells and allogeneic dendritic cells.
- Administration of hybrid cell vaccine to 17 patients with metastatic RCC.
- Monitoring of clinical response and induction of cytotoxic T lymphocyte (CTL) activity.
Main Results:
- Four out of 17 patients achieved complete rejection of metastatic lesions.
- One patient showed a mixed response, and two experienced >50% tumor mass reduction.
- Demonstrated induction of HLA-A2-restricted CTLs targeting the Muc1 antigen and CD8+ lymphocyte infiltration at tumor sites.
Conclusions:
- Hybrid cell vaccination is a safe and effective therapeutic approach for metastatic RCC.
- The strategy shows potential for broad applicability in other malignancies.
- The therapy successfully elicits tumor-specific immune responses.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...